Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 1998

View Archived Issues

Nutritional supplementation in HIV-infected patients

Company Profile: Genome Therapeutics

Sequus: Q4 and FY 1997 highlights

Safety and efficacy of thalidomide in HIV-positive patients

Cell Genesys: Q4 and FY 1997 highlights

Remune is safe and well tolerated in the treatment of HIV infection

Antitumor arabinofuranosylcytosines from Yamasa

Sankyo researches new antidiabetic agents

Coulter: Q4 and FY 1997 highlights

Shaman: Q4 and FY 1997 highlights

Successful results contribute to early termination of phase IIa study of TBC-11251

Phase III milestone reached for Ethyol in new indication

Recordati continues clinical development of BPH Rx

DuPont Merck claims new CRF antagonists

Development of HIV gene therapy discontinued

Antipsychotic drugs in development at Janssen

Nonpeptide GnRH antagonists prepared at Merck & Co.

Pharmacia & Upjohn reveals novel compounds and novel methods of treating NIDDM

HGS's KGF-2 enters clinical testing

Chiroscience describes series with PDE/TNF-inhibitory properties

Roche discloses new 5-HT2B antagonists

Biphenylsulfonamides with MMP-inhibitory effects developed at Warner-Lambert

Weizmann Institute presents new materials for PDT of cancer

SS Pharm. licenses AChE inhibitor to Arena

NICHD develops experimental E. coli O157 vaccine

Pamidronate beneficial in multiple myeloma with bone complications

Pharmacokinetic/pharmacodynamic characterization of CP-105696 in volunteers

New antiobesity agent now being distributed in U.S.

GTS-21 protects against amnesia, neuronal death in gerbil model of cerebral ischemia

SDZ-RAD: a novel immunosuppressant progresses in the Novartis pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...